MedDataX Logo

Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis

NCT ID: NCT00375635

Last Updated: 2006-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to examine removal of protein bound uremic substances by mFPSA in chronic hemodialysis patients. mFPSA is an extracorporal blood purification system developed for detoxification in acute liver failure by removal of protein bound as well as water soluble substances.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Measurements of uremic protein bound substances before and after mFPSA and a preceding routine hemodialysis session.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uremia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

mFPSA Uremic toxins Protein bound toxins Uremia Chronic hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mFPSA treatment

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over the age of 18
* Anuria
* Chronic hemodialysis dependence

Exclusion Criteria

* No present history of bleeding episodes
* Cardiac diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mette B Damholt, MD,Ph.d.

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet P2132

Soren D Ladefoged, MD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rigshospitalet

Copenhagen, Copenhagen, Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mette B Damholt, MD,Ph.d.

Role: CONTACT

Phone: +45 35453545

Email: [email protected]

Soren D Ladefoged, MD

Role: CONTACT

Phone: +45 35453545

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mette B Damholt, MD,Ph.d.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MBD2006

Identifier Type: -

Identifier Source: org_study_id